

# B

## APPENDIX

### AGENTS IMPLICATED IN DRUG-INDUCED THROMBOEMBOLIC DISEASES

Drug	Incidence	Level of Evidence <sup>a</sup>
<b>Hemostatic Agents</b>		
Aminocaproic acid	NK	C
Aprotinin	1%	B
Cyanoacrylate	NK	C
Desmopressin	NK	C
Eptifibatide	NK	C
Protamine sulfate	NK	B
Activated prothrombin complex concentrate	NK	B
3-factor prothrombin complex concentrate	0.7%	B
4-factor prothrombin complex concentrate	1.8%	B
Recombinant factor VIIa	7–9.4%	A
Tranexamic acid	NK	C
<b>Anticoagulants</b>		
Heparin	1–5% develop HIT, 25–50% of those develop HITT	B <sup>a</sup>
Low-molecular-weight heparin	2.2%	B <sup>a</sup>
Pentosan	NK	B
Streptokinase	NK	C
Urokinase	NK	C
Warfarin (coumarin derivatives)	NK	B

(continued)

Drug	Incidence	Level of Evidence <sup>a</sup>
<b>Hematopoietic Agents</b>		
Darbepoetin	3.3–8%	A
Erythropoietin	3.3–26.7%	A
G-CSF	NK	B
GM-CSF	NK	B
<b>Estrogen-Containing Agents</b>		
Diethylstilbestrol	6.8–7%	A
Oral contraceptives	6 times the risk of nonusers; 1–2/10,000 woman-year	A
Hormone replacement	0.2–5.9/100 woman-year	A
<b>Antiandrogens</b>		
Cyproterone	5.23 increased odds	B
Flutamide	5%	B <sup>a</sup>
Goserelin	1–5%	B
Leuprolide	16.7%	A
<b>Selective Estrogen-Receptor Modulators</b>		
Raloxifene	9.5/100 woman-year	A
Tamoxifene	3.6–12/100 woman-year	A
Toremifene	1.5%	B
<b>Aromatase Inhibitors</b>		
Anastrozole	1–2.2%	A
Letrozole	NK	C
<b>Androgenic Agents</b>		
Danazol	NK	C
Nandrolone	NK	C
Megestrol	4.9%	B <sup>a</sup>
<b>Follicle-Stimulating Hormone</b>		
Follitropin alfa	NK	C
<b>Antineoplastic Agents</b>		
Aldisleukin	<1%	B
Asparaginase	11–36.7%	A
Basiliximab	3–10%	B

(continued)